Coverage
Filings
Zealand Pharma on Thursday reported a significant surge in revenue and profit for the first nine months of 2025, driven by its recent partnership with Roche, while also announcing it has paused development of its experimental obesity drug, dapiglutide.
Zealand Pharma's revenue and profit soared in the first half of 2025, a direct result of a major partnership with Roche to develop its new weight-loss drug candidate, petrelintide.
Zealand Pharma on Wednesday reported positive results from a mid-stage study of its experimental obesity drug, dapiglutide, showing an average body weight reduction of 11.6% over 28 weeks.
| 3 Jul 2017 |
| Total number of shares and voting rights in Zealand at June 30, 2017 | 3 Jul 2017 |
| Phase 2a trial results support development of dasiglucagon in the iLet pump system for type 1 diabetes | 22 Jun 2017 |
| Glepaglutide meets primary endpoint in Phase 2 trial in patients with short bowel syndrome | 19 Jun 2017 |
| Zealand increases its share capital as a consequence of exercise of employee warrants | 15 Jun 2017 |